In our study, we have found HNF1B mutations (VUS – variant of uncertain significance) in 1/77 cases (1.3%) only, which is in accordance with the TCGA study showing only one likely pathogenic mutation in a dataset containing 491 cases of prostate cancer (0.2%). This evidence concerns the gene HNF1B and prostate carcinoma.